AssociationofGeneticVariantsinNUDT15WithThiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
暂无分享,去创建一个
M. Rivas | M. Daly | R. Xavier | J. Barrett | M. Parkes | J. Mansfield | Fraser Cummings | M. Weedon | C. Anderson | A. Ananthakrishnan | M. Voskuil | D. McGovern | H. Sokol | V. Andersen | A. Hart | R. Russell | V. Annese | N. Kennedy | G. Heap | D. Gaya | K. Subramaniam | S. Sebastian | J. Lindsay | D. Rampton | J. Halfvarson | M. Schultz | T. Florin | P. Seksik | L. Beaugerie | P. Irving | A. Todd | R. Fedorak | N. Heerasing | P. Ellul | R. Pollok | J. Goodhand | E. Festen | J. Koskela | S. Ramakrishnan | S. Jones | C. Bewshea | G. Walker | A. Cole | K. Weersma | P. Hendy | Abhey Singh | JamesW. Harrison
[1] F. Carrat,et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. , 2018, Gastroenterology.
[2] U. Hofmann,et al. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. , 2018, Blood.
[3] Y. Méndez,et al. TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay , 2018, British journal of haematology.
[4] M. Relling,et al. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. , 2017, Blood.
[5] Motohiro Kato,et al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia , 2017, Pharmacogenetics and genomics.
[6] Swarup A. V. Shah,et al. Nucleoside diphosphate‐linked moiety X‐type motif 15 C415T variant as a predictor for thiopurine‐induced toxicity in Indian patients , 2017, Journal of gastroenterology and hepatology.
[7] Xueding Wang,et al. NUDT15 polymorphisms are better than thiopurine S‐methyltransferase as predictor of risk for thiopurine‐induced leukopenia in Chinese patients with Crohn's disease , 2016, Alimentary pharmacology & therapeutics.
[8] Shane A. McCarthy,et al. Reference-based phasing using the Haplotype Reference Consortium panel , 2016, Nature Genetics.
[9] D. McGovern,et al. Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility , 2016, Expert review of clinical immunology.
[10] D. Gurwitz,et al. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies , 2016, The Pharmacogenomics Journal.
[11] U. Hofmann,et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity , 2016, Nature Genetics.
[12] M. Tremelling,et al. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.
[13] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[14] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[15] Y. Kakuta,et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD , 2015, The Pharmacogenomics Journal.
[16] R. Wade,et al. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003 , 2015, British journal of haematology.
[17] M. Relling,et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Tremelling,et al. HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants , 2014, Nature Genetics.
[19] Jianjun Liu,et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia , 2014, Nature Genetics.
[20] Richard Durbin,et al. Efficient haplotype matching and storage using the positional Burrows–Wheeler transform (PBWT) , 2014, Bioinform..
[21] Iuliana Ionita-Laza,et al. Sequence kernel association tests for the combined effect of rare and common variants. , 2013, American journal of human genetics.
[22] J. Mate,et al. Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients , 2013, Inflammatory bowel diseases.
[23] R. V. Schaik,et al. A clinical approach to pharmacogenetics. , 2013 .
[24] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[25] M. Pirmohamed,et al. Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool , 2011, PloS one.
[26] O. Dewit,et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. , 2011, Clinical biochemistry.
[27] P. Visscher,et al. GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.
[28] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[29] J. Gisbert,et al. Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review , 2008, The American Journal of Gastroenterology.
[30] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[31] R. Gearry,et al. Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease , 2005, Journal of gastroenterology and hepatology.
[32] D. Gaffney,et al. Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.
[33] P. J. Kelly,et al. Inflammatory bowel disease: epidemiology and management in an English general practice population , 2000, Alimentary pharmacology & therapeutics.
[34] B. Bonaz,et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.
[35] U. Klotz,et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. , 2007, Clinical pharmacokinetics.